

Advanced Cell Processing for Next-Generation Therapies

Tony Ward, CTO Meeting on Mesa 2023

Curate Biosciences at a glance

- Privately Held, Located in Carlsbad, Ca.
 - VC and Biopharma backed
- Unique Centrifuge free cell processing platform
 - Consistent WBC recovery with unequalled purity and highest cell vitality
 - Available in US in 2023
- Interested in
 - Partnering
 - Co-development
 - Licensing/Tech
 - Regional Expansion (Asia)



Our Value Proposition:

The proprietary microfluidic Curate System will provide unparalleled starting cell product quality to enhance the cell therapy manufacturing process and improve outcomes for patients



Disclaimer

All statements and information in this presentation, other than statements of historical fact are forward-looking statements (within the meaning of the federal securities laws) based on assumptions concerning future conditions that ultimately may prove to be inaccurate. These forward-looking statements may be identified by words such as "believe", "anticipate", "contemplate" and "expect". Many phases of our operations are subject to influences outside our control. Any one or any combination of factors could have a materially adverse effect on our business, financial condition and results of operations. These factors include competitive pressures, economic conditions, governmental regulation and policies and a variety of other conditions. Accordingly, if the estimates and assumptions underlying the information in this presentation are not achieved or proven to be invalid, actual results will differ from those projected, and the difference may be material.

We caution investors not to unduly rely on any forward-looking statements. The forward-looking statements speak only as of the date hereof. Curate Biosciences has no duty to update any of these forward-looking statements after the date hereof, nor to conform prior statements to actual results or revised expectations.

Curate[®], Curate[®] Cell Processing System, and Deterministic Cell Separation[™] (DCS[™]) are trademarks of Curate Biosciences. The products and techniques presented herein are not approved by the FDA to diagnose, treat, cure or prevent any disease.



What are the ways that Curate's microfluidic DCS processing improves process?

Key Objectives



Optimal Recovery Esp. Younger T cells



Highest Purity



Consistent **Expansion & Yields**



Highly Engineerable









Inconsistent **Sub-optimal Recovery**



Variable, **Poor Purity**



Inconsistent Yield²



Inconsistent Engineerability



Pelleting/Chemicals

- 1. Legend CEO talking about Carvykti Fierce Biotech Interview (12/22)
- 2. 20% of people are dying before they can get the CAR-T (Endpoints, MD-Anderson 3/23)



Curate Biosciences | www.curatebio.com

Curate Benefits



Consistent **Unbiased Recovery** of all T subsets

/	
	Mara
$\langle $	/
1	


Industry **Leading Purity**

Improved, **Consistent Yield**


Highly Engineerable




Unperturbed



Microfluidic Deterministic Cell Separation[™] (DCS) and its key benefits:




- Gentle, uniform processing with virtually no cell loss (Array efficiency: 96.5%)
- Same device separates, **washes**, concentrates individual cells in <u>single</u> process.
 - Processing rate of 50x10⁹ WBC/Hr
 - >3 Log wash in <1 second
- <u>Requires no Ammonium chloride, Ficoll</u>
- Does not pellet cells






Legacy Technologies are highly variable and force cell-cell Interactions



Contamination Data is from non-Curate evaluations of each platform. Spinning Membrane is Mfg. data with platelet depletion program (~80% depletion) as presented by FHCRC at ISCT '2023, Direct from assumes 99% efficient plt removal




DCS Wash improves *Pathway Specific* Impact on Prototypic CAR-T Process:




Detailed data may be found at: www.curatebio.com/publications/WhitePaper



Elimination of lytic agents and centrifugal processes improves active mitochondrial mass in expanded T cells up to 40%






T cells exposed to Ficoll, Ammonium Chloride or <u>-ve</u> <u>selection</u> directly from start matrix

Non-DCS T cells have significantly lower mass vs. DCS processed, then negatively selected T cells

Ratio of Mitobrilliant staining normalized to DCS preparations and compared over time.




DCS prepared T cells show a less altered phosphorylation profile vs. Ficoll or Ammonium Chloride Exposed Cell



2. Response to oxidative stress



Post thaw processing confirms that PBMC are epigenetically redirected




3. Araki et al. Genome-wide Analysis of Histone Methylation Reveals Chromatin State-Based Regulation of Gene Transcription and Function of Memory CD8+ T Cells. Immunity 30, 912–925, June 19, 2009 DOI 10.1016/j.immuni.2009.05.006




Curate Biosciences | www.curatebio.com

Cell:Cell contact during centrifugal processing is a <u>significant</u> driver of methylation state







Processing and Environment Drive Differential Methylation in isolated T cells



observation

- Purified T-cell methylation shifts as a function of sample preparation methodology
- Positive and Negative Selection impact methylation states differently (likely due to antibody binding effect)








Curate Biosciences | www.curatebio.com

Environment & processing drive Histone (H3K27) tri-methylation changes in T cell memory subtypes




Observation

- Hypo-methylation bias particularly present in CD4, CD8 naïve T cells
- CD4+ Tcm , Temra also significantly lower
- DCS cells are uniquely less methylated vs. **both** Ficoll/Direct Selection
 - Consistent with platelet/cytokine removal



Histone Methylation is a highly conserved potent regulator of Gene Silencing, Cell Differentiation




Figures Adapted from Biorender, The functions of EZH2 in immune cells: Principles for novel immunotherapies, J Leukocyte Bio. 10.1002/JLB.1RU0520-311R

- 4. Long, Y. et al. RNA is essential for PRC2 chromatin occupancy and function in human pluripotent stem cells. Nat Genet 52, 931–938 (2020)
- 5. Kfoury-Beaumont, N. et al. The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential. BMC Biol 20, 124 (2022)
- 6. Schuettpelz, L et al. Regulation of hematopoietic stem cell activity by inflammation Front. Immunol., 19 July 2013 https://doi.org/10.3389/fimmu.2013.00204



Curate Biosciences | www.curatebio.com

How do you want your cells to arrive when you start processing?







Curate DCS cells are metabolically and epigenetically superior vs. centrifuged cells


- DCS cells are uniquely fit for purpose
- All data aligns with higher clinical efficacy
 - Highest metabolic potential
 - Most retention of Naïve Tscm/Tcm phenotype
 - Less generation of Treg
 - Physically and more epigenetically available Naïve
 CD4+ cells are available for transcription

- Metabolically more fit
 - Up to 40% more mitochondrial mass
- More able to signal properly
 - No Oxidative stress response
 - Up to 40% more phosphorylation vs Ammonium Chloride exposed cells
 - Less activation
 - □ Up to 15% less phosphorylation vs Ficoll processed cells
- Lower DNA Methylation state
 - DCS cells likely start in a similar state as retraining with Dasatinib/Tazemetostat which target PRC2/EZH2/H3K27 Trimethylation
 - CAR-T "reversed" to Tscm status with drug pulses improves efficacy and potency in clinical studies, but takes days/weeks to achieve¹
 - Hypomethylation phenotype seen in DCS vs. all centrifugal approaches tested

1. Weber et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science . 2021 Apr 2;372(6537):eaba1786. doi: 10.1126/science.aba1786.



Curate's technical advantage is derived from three discrete areas:






The Curate System delivers uniquely well-prepared cells with uniquely good consistency...



Functionally closed
Easy to use, minimal hands-on time
Processes unfiltered leukopak to PBMC in <1 hour
cGMP-grade solution
21-CFR-11, Networkable



techsupport@curatebio.com

